Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Doxycycline Monohydrate, Vibramycin Monohydrate®
Doxycycline · 2 trials · 1 indication
Bioequivalence based on Cmax.
Bioequivalence based on AUC0-t.
Bioequivalence based on AUC0-inf.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Doxycycline Monohydrate |
| 2 | ACTIVE_COMPARATOR | Vibramycin Monohydrate® |
| Name | Type | Description |
|---|---|---|
| Doxycycline Monohydrate | DRUG | 25 mg 5 mL dose |
Inclusion Criteria All subjects must satisfy the following criteria to be considered for study participation: * Subject must be male or non-pregnant, non-breast-feeding female * Subject must be at least 18 years of age * Subject must have a Body Mass Index (BMI) between 18 and 30 kg/m2, inclusive,...
Doxycycline is a small molecule drug developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. It is being studied in Phase 1 clinical development. The specific therapeutic indication for this program has not been disclosed, and the therapeutic area is classified as other.
Doxycycline targets MMP8, MMP1, MMP13, and MMP7. It acts as an inhibitor of these matrix metalloproteinases. This target profile places it in the inhibitor class of small molecule therapeutics.
Doxycycline is developed by Teva Pharmaceutical Industries Limited, which is listed on the stock exchange under the ticker symbol TEVA. Teva is the sponsor behind the clinical program for this small molecule MMP inhibitor.
Doxycycline is in Phase 1 clinical development. It is an investigational drug and is not approved for the undisclosed indication being studied. Two Phase 1 trials have been completed, and no trials are currently active.
Doxycycline has been evaluated in two completed Phase 1 trials. NCT00829790 studied doxycycline monohydrate 25 mg (5 mL) oral suspension under fed conditions, and NCT00829764 studied the same formulation under fasting conditions. Both enrolled 30 healthy volunteers in the United States, for a total enrollment of 60 participants.
Yes, Doxycycline Monohydrate is an alternative name for Doxycycline. The two completed Phase 1 trials used doxycycline monohydrate 25 mg (5 mL) oral suspension, so readers searching for doxycycline monohydrate are looking at the same drug asset developed by Teva Pharmaceutical Industries Limited.